Dual: Multi-pronged attack
Dual developing PP2A activators to disrupt multiple cancer-associated pathways
Dual Therapeutics LLC is developing first-in-class oral small molecules that directly activate protein phosphatase 2 to disrupt multiple cancer pathways simultaneously. By restoring the phosphatase's activity to normal levels, the approach could treat prostate cancers that are resistant to anti-androgens and chemotherapy.
D. Amy Trainor, a venture